Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I‐labelled anti‐tenascin monoclonal antibody BC‐2

No abstract is available for this paper.

• Publication year

  1992

• Venue

  International Journal of Cancer

• Publication date

  1992-04-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.2910510103PMID 1373410
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of metastatic colorectal cancer by means of specific monoclonal antibodies conjugated with iodine-131: a phase II study.

  1991cited by this paper
• Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues

  1991cited by this paper
• Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies.

  1991cited by this paper
• Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration.

  1990cited by this paper
• Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer.

  1990cited by this paper
• Intraperitoneal radioimmunotherapy for ovarian cancer

  1990cited by this paper
• Tenascin: A hexameric adhesive glycoprotein

  1989cited by this paper
• Intraperitoneal radioimmunotherapy for ovarian cancer

  1989cited by this paper
• Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study.

  1989cited by this paper
• Influence of anesthetics--nitrous oxide in particular--on electromyographic response evoked by transcranial electrical stimulation of the cortex.

  1989cited by this paper
• Cerebral distribution of immunoconjugate after treatment for neoplastic meningitis using an intrathecal radiolabeled monoclonal antibody.

  1989cited by this paper
• Locoregional immunotherapy of human ovarian cancer: preliminary results.

  1989cited by this paper
• Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.

  1989cited by this paper
• A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples.

  1989cited by this paper
• The role of chemotherapy in the treatment of gliomas in adults.

  1989cited by this paper
• Structure and Operation of the EGS4 Code System

  1988cited by this paper
• Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.

  1988cited by this paper
• [Radioimmunotherapy of solitary liver metastases using intratumor instillation of 131I-labeled monoclonal antibodies--initial results of a clinical study].

  1988cited by this paper
• Radioimmunbehandlung solitärer Lebermetastasen mittels intratumoraler Instillation 131J-markierter monoklonaler Antikörper - Erste Ergebnisse einer klinischen Studie

  1988cited by this paper
• Hexabrachion Protein (Tenascin, Cytotactin, Brachionectin) in Connective Tissues, Embryonic Brain, and Tumors

  1988cited by this paper
• Radioimaging of Melanoma and CEA Secreting Tumours by Monoclonal Antibodies Performed by Different Routes of Administration

  1988cited by this paper
• Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy.

  1987cited by this paper
• Immunoscintigraphy of colorectal carcinoma with F (ab')2 fragments of anti-CEA monoclonal antibody.

  1987cited by this paper
• Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms.

  1986cited by this paper
• EGS4 code system

  1985cited by this paper
• Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study

  1983cited by this paper
• ROUTINE INDUCTION OF LABOUR WITH EXTRA‐AMNIOTIC PROSTAGLANDIN E2 IN A VISCOUS GEL

  1979cited by this paper
• Neoplasms of the central nervous system.

  1977cited by this paper
• A schema for absorbed-dose calculations for biologically-distributed radionuclides.

  1968cited by this paper
• Assessment of thyroid function and anatomy with technetium-99m as pertechnetate.

  1968cited by this paper

• Innovative radiotherapies for the treatment of glioblastoma

  2025cites this paper
• Do we need dosimetry for optimization of theranostics in CNS tumors?

  2024cites this paper
• Tenascin-C targeting strategies in cancer.

  2024cites this paper
• IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors

  2024cites this paper
• Clinical advances in TNC delivery vectors and their conjugate agents.

  2023cites this paper
• Clinical application of radioiodinated antibodies: where are we?

  2022cites this paper
• A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma

  2021cites this paper
• Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo

  2020cites this paper
• Potential for Nuclear Medicine Therapy for Glioblastoma Treatment

  2019cites this paper
• Chapter 22 – Targeted Radionuclide Therapy

  2016cites this paper
• Identification of two novel Chlorotoxin derivatives CA4 and CTX-23 with chemotherapeutic and anti-angiogenic potential

  2016cites this paper
• Targeted delivery of immunomodulatory proteins: evaluation of novel antibody-chemokine and antibody-cytokine fusion proteins for cancer therapy

  2015cites this paper
• Silylated precision particles for controlled release of proteins.

  2015cites this paper
• Emerging classes of armed antibody therapeutics against cancer

  2014cites this paper
• The new golden era for radioimmunotherapy: not just for lymphomas anymore.

  2013cites this paper
• Locoregional Radionuclide Therapy of Primary and Metastatic Cancers

  2012cites this paper
• Chapter 22 – Targeted Radionuclide Therapy—Expanded Content

  2012cites this paper
• Radioimmunotherapy of Brain Tumors

  2012cites this paper
• Preparation and In Vitro Evaluation of 131I-BmK CT as a Glioma-Targeted Agent

  2010cites this paper
• Unmet Medical Needs in Glioblastoma Management and Optimal Sequencing of the Emerging Treatment Options

  2009cites this paper
• Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting

  2009cites this paper
• Targeted radionuclide therapy.

  2008cites this paper
• Review: Intracavitary Radioimmunotherapy to Treat Solid Tumors

  2008cites this paper
• Radioimmuntherapie maligner Gliome

  2008cites this paper
• Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.

  2007cites this paper
• Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies

  2007cites this paper
• The specific delivery of radloisotopes to a tumor at minimal radiation of normal tissue is the ultimate aim of radioimmunetherapy. In this

  2006cites this paper
• Use of Monoclonal Anti-EGFR Antibody in the Radioimmunotherapy of Malignant Gliomas in the Context of EGFR Expression in Grade III and IV Tumors

  2006cites this paper
• Tenascin distribution in human brain tumours

  2005cites this paper
• Local and systemic toxicity of h-R3, an anti-epidermal growth factor receptor monoclonal antibody, labeled with 188osmiun after the intracerebral administration in rats.

  2005cites this paper
• Radioimmunotherapy: no news from the newcomer

  2005cites this paper
• Intralesional administration of I-131 labelled monoclonal antibodies in the treatment of malignant gliomas

  2005cites this paper
• An antibody-interferon gamma fusion protein for cancer therapy

  2004cites this paper
• Molecular targeting of angiogenesis.

  2004cites this paper
• Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice

  2004cites this paper
• Molecular targeting of angiogenesis for imaging and therapy

  2004cites this paper
• Comparative Biodistribution of Potential Anti- Glioblastoma Conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in Normal Mice

  2004cites this paper
• [111In]Bz-DTPA-hEGF: Preparation and In Vitro Characterization of a Potential Anti-Glioblastoma Targeting Agent

  2003cites this paper
• Expression of tenascin‐C in various human brain tumors and its relevance for survival in patients with astrocytoma

  2003cites this paper
• Immunotherapy and biological modifiers for the treatment of malignant brain tumors.

  2003cites this paper
• [Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV)].

  2002cites this paper
• Simultaneous radiotherapy and radioimmunotherapy of malignant gliomas with anti-EGFR antibody labelled with iodine 125. Preliminary results.

  2002cites this paper
• Recent advances in radionuclide therapy.

  2001cites this paper
• Radionuclide Dosimetry and Radioimmunotherapy of Cancer

  2000cites this paper
• Clinical radioimmunotherapy.

  2000cites this paper
• Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach

  2000cites this paper
• Therapeutic Efficacy of Intralesional 131I-labelled Hyaluronectin in Grafted Human Glioblastoma

  2000cites this paper
• Clinical significance of tenascin-C expression in osteosarcoma: tenascin-C promotes distant metastases of osteosarcoma.

  2000cites this paper
• Glioma-associated Antigen Expression in Oligodendroglial Neoplasms: Tenascin and Epidermal Growth Factor Receptor

  2000cites this paper
• Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.

  1999cites this paper
• 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study.

  1999cites this paper
• 131 I Radioconjugated Antibodies for the Locoregional Radioimmunotherapy of High-grade Malignant Glioma

  1999cites this paper
• Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody.

  1999cites this paper
• Comparison of Interlesionally and Systemically Administered Radiolabelled Monoclonal Antibodies in Implanted Tumours

  1999cites this paper
• Affinity reagents against tumour-associated extracellular molecules and newforming vessels.

  1998cites this paper
• Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas

  1997cites this paper
• Biologic and oncologic implications of tenascin-C/hexabrachion proteins.

  1997cites this paper
• Distribution of tenascin in human malignant gliomas is not related to cell proliferation.

  1997cites this paper
• Targeting Peptides for Pleural Cavity Tumor Radiotherapy: Specificity and Dosimetry of Re-188-RC-160

  1997cites this paper
• Lymphocyte adhesion molecule ligands and extracellular matrix proteins in gliomas and normal brain: expression of VCAM-1 in gliomas

  1997cites this paper
• Spontaneous intracranial hypotension: MRI and radionuclide cisternography findings.

  1997cites this paper
• Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy.

  1997cites this paper
• Design, Synthesis, and Cellular Delivery of Antibody Targeted, Radiolabelled Oligonucleotide Conjugates for Cancer Therapy

  1996cites this paper
• Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel.

  1996cites this paper
• Experimental radiotherapy of receptor‐positive human prostate adenocarcinoma with 188Re‐RC‐160, a directly‐radiolabeled somatostatin analogue

  1996cites this paper
• Biologic Considerations in Targeting Brain tumors for Boron Neutron Capture Therapy

  1996cites this paper
• Tenascin in human neoplasia.

  1996cites this paper
• Targeting of Drugs 5

  1996cites this paper
• Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors.

  1995cites this paper
• In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.

  1995cites this paper
• [Radioimmunotherapy of malignant diseases. Value and prospects].

  1995cites this paper
• Improved Control of Malignant Gliomas by Means of Intralesional Radioimmunotherapy

  1995cites this paper
• Necrosis of malignant gliomas after intratumoral injection of 201TI in vivo in the rat

  1995cites this paper
• Review : Glial Boundaries and Scars: Programs for Normal Development and Wound Healing in the Brain

  1995cites this paper
• Multimodal Image Registration for Radioimmunotherapy. Surface Landmark and Frame Based Correlation in Patients Undergoing Intralesional 131I-MAb Therapy for Recurrent High Grade Glioma

  1995cites this paper
• Monoclonal antibody against human glioblastoma multiforme (U-87MG) immunoprecipitates a protein of molecular mass 38 kDa and inhibits tumor growth in nude mice.

  1995cites this paper
• Intralesional radiolabelled monoclonal antibody therapy.

  1995cites this paper
• Dosimetry of Intralesional 131I-Monoclonal Antibody (MAb) Therapy in Patients with Recurrent High Grade Gliomas

  1995cites this paper
• Radioimmunotherapy with Monoclonal Antibodies

  1994cites this paper
• Prospects for Cancer Imaging and Therapy with Radioimmunoconjugates

  1994cites this paper
• Radioimmunotherapy with monoclonal antibodies. A new horizon in nuclear medicine therapy?

  1994cites this paper
• Local administration of 7 beta-hydroxycholesteryl-3-oleate inhibits growth of experimental rat C6 glioblastoma.

  1994cites this paper
• Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression.

  1994cites this paper
• In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer.

  1994cites this paper
• Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors

  1994cites this paper
• [Radioimmunotherapy in the treatment of cancers].

  1994cites this paper
• Antibody-targeted drugs for the therapy of cancer.

  1994cites this paper
• Radioimmunotherapy of Gastrointestinal Cancer and Glioblastomas

  1993cites this paper
• Progress review: intrathecal and intratumoral injection of radiolabelled monoclonal antibodies (MoAbs) for the treatment of central nervous system (CNS) malignancies.

  1993cites this paper
• Tenascin and other adhesion-modulating proteins in cancer.

  1993cites this paper
• The therapeutic challenge of gliomas.

  1993cites this paper
• Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy

  1993cites this paper
• Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues

  1992cites this paper